Threshold Pharmaceuticals | Date: 2015-07-15
The present invention provides a new method for making TH-302 and solid forms thereof. The compound in its solid form is an effective anti-cancer agent and may be used in various pharmaceutical compositions, and are particularly effective for the treatment of cancer. The invention also provides a method for preparing such compounds and forms and for treating cancer in a mammal comprising the step of administering a therapeutically effective amount of a solid form of TH-302 thereof.
Threshold Pharmaceuticals | Date: 2015-12-07
Methods for the treatment of cancer are described. In particular, methods for treatment of cancer comprising administration of glufosfamide alone or in combination with another anticancer agent are disclosed.
Threshold Pharmaceuticals and Merck Patent Gmbh | Date: 2014-07-23
Combined administration of a hypoxia-activated prodrug, such as TH-302, a taxane, such as nab-paclitaxel, and a nucleoside analog chemotherapeutic, such as gemcitabine, are efficacious in the treatment of cancer, including pancreatic cancer.
Threshold Pharmaceuticals | Date: 2014-06-27
The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.
Threshold Pharmaceuticals | Date: 2013-01-30
CA-IX levels are predictive of the probability that a cancer patient will respond favorably to cancer therapy involving administration of a hypoxia-activated prodrug. In a first aspect, the present invention provides a method for treating cancer comprising the steps of measuring CA-IX levels in a sample isolated from the patient, and administering a hypoxia-activated prodrug only if the CA-IX level measured is equal to or greater than about 30 pg/mL (e.g. 28.8 pg/mL) CA-IX protein in a serum sample, as may be measured, for example or without limitation, using an ELISA. In one embodiment, a HAP is administered if the measured CA-IX level is equal to or greater than about 75 pg/mL (e.g. 77.1 pg/mL) protein in a serum sample. Thus, in one embodiment, the CA-IX level is measured based on the amount of CA-IX protein in a serum sample.
Threshold Pharmaceuticals | Date: 2013-02-21
This invention provides medicines and technology for use in treating cancer. The approach is to administer a hypoxia activated prodrug, followed by administration of another chemotherapeutic agent that is not a hypoxia activated prodrug. The median survival in pancreatic cancer patients can be extended by several months using such medicines and technology. This invention also provides methodology to assist the clinician in identifying subjects who will benefit most from the therapy. Drug combinations are provided to help the clinician manage side effects that may occur in the course of treatment.
Threshold Pharmaceuticals | Date: 2016-01-29
Administration of Glufosfamide alone and in combination with another anticancer agent is useful for the treatment of gall bladder cancer.
Threshold Pharmaceuticals | Date: 2013-12-11
The invention provides a protected anti-neoplastic agent of the formula Hyp-N, wherein N is an anti-neoplastic agent and a protectable hydroxyl group of the anti-neoplastic is substituted with Hyp; Hyp is a moiety having the formula:R_(2) is hydrogen;R_(3) is hydrogen or C_(1)-C_(6) alkyl;R_(1) is C_(1)-C_(6) alkyl or C_(1)-C_(6) alkoxy, optionally substituted with one or more heteroatom-containing groups; andR_(4) is hydrogen, C_(1)-C_(6) alkyl, or C_(1)-C_(6) alkoxy, optionally substituted with one or more heteroatom-containing groups.
Threshold Pharmaceuticals | Date: 2014-04-09
Cancer patients likely to respond to HAP treatment exhibit tumor tissues with high levels of hypoxia, which can be measured using PET imaging with [18F]-HX4.
Threshold Pharmaceuticals | Date: 2013-12-10
Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.